{
  "meta": {
    "title": "Liver Safety & Hepatotoxicity",
    "subtitle": "A scientific analysis of the Kava liver controversy: facts, myths, and the current state of research.",
    "category": "Safety",
    "breadcrumbs": {
      "home": "Home",
      "sicherheit": "Safety",
      "current": "Liver Safety"
    }
  },
  "toc": {
    "title": "Contents",
    "zusammenfassung": "Summary",
    "verbot2002": "The Ban of 2002",
    "wasWirklichGeschah": "What Really Happened",
    "rehabilitation": "Rehabilitation & Court Rulings",
    "wissenschaft": "The Scientific Evidence",
    "whoBewertung": "WHO Assessment 2007",
    "emaBewertung": "EMA Assessment 2017",
    "klinischeStudien": "Clinical Studies",
    "risikofaktoren": "Identified Risk Factors",
    "extrakte": "Extract Types",
    "pflanzenteile": "Plant Parts",
    "genetik": "Genetic Factors",
    "komedikation": "Comedication & Alcohol",
    "mechanismen": "Possible Mechanisms",
    "empfehlungen": "Practical Recommendations",
    "quellen": "Sources"
  },
  "navigation": {
    "continueTitle": "Continue in the Safety Chapter",
    "items": [
      {
        "title": "Overview",
        "href": "/de/sicherheit",
        "description": "Back to the Safety Overview"
      },
      {
        "title": "Interactions",
        "href": "/de/sicherheit/wechselwirkungen",
        "description": "Medications & CYP450 Interactions"
      },
      {
        "title": "Contraindications",
        "href": "/de/sicherheit/kontraindikationen",
        "description": "When Kava should be avoided"
      }
    ]
  },
  "zusammenfassung": {
    "title": "Current Scientific Consensus",
    "intro": "After comprehensive analyses by WHO, EMA, and independent researchers, the following is concluded:",
    "points": [
      "Traditionally prepared Kava from Noble varieties is <strong>safe</strong> when used properly",
      "Severe liver damage is <strong>extremely rare</strong> (estimated incidence: 1:60,000 to 1:1,000,000)",
      "Most case reports exhibited <strong>significant quality deficiencies</strong> in causality assessment",
      "The EU ban of 2002 was deemed <strong>disproportionate</strong> by German courts"
    ]
  },
  "verbot2002": {
    "title": "The Ban of 2002",
    "intro": "In 2002, Kava was removed from the market in Germany and many other European countries. The Federal Institute for Drugs and Medical Devices (BfArM) revoked the approvals for Kava-containing medicines after reports of severe liver damage were received. This decision had far-reaching consequences for the global Kava market and the Pacific producing countries.",
    "chronologie": {
      "title": "Chronology of Events",
      "note": "For detailed information on the current legal status in various countries, see",
      "linkText": "Legal Status & Legality",
      "events": [
        {
          "date": "1998-2001",
          "text": "First case reports of liver damage in Kava users in Europe"
        },
        {
          "date": "Nov 2001",
          "text": "BfArM orders phased procedure"
        },
        {
          "date": "Jun 2002",
          "text": "Revocation of approvals in Germany"
        },
        {
          "date": "2002-2003",
          "text": "Bans in UK, France, Switzerland, Canada, Australia"
        },
        {
          "date": "2014",
          "text": "Administrative Court of Cologne declares ban unlawful"
        },
        {
          "date": "2015",
          "text": "OVG Münster confirms: Ban was disproportionate"
        },
        {
          "date": "2019",
          "text": "Revocation of drug approvals finally lifted"
        }
      ]
    }
  },
  "wasWirklichGeschah": {
    "title": "What Really Happened: A Critical Analysis",
    "intro": "The original case reports that led to the ban were intensively studied in the following years. Significant methodological deficiencies were revealed:",
    "probleme": {
      "title": "Problems with the Case Reports",
      "items": [
        "Incomplete documentation in over 50% of cases",
        "No standardized causality assessment (RUCAM)",
        "Comedication with hepatotoxic substances ignored",
        "Alcohol consumption often undocumented",
        "Product quality and plant parts unclear"
      ]
    },
    "erkenntnisse": {
      "title": "Later Findings",
      "items": [
        "Many products contained above-ground plant parts",
        "Acetonic extracts showed higher risk than aqueous ones",
        "Tudei Kava was sometimes sold as Noble",
        "Mold contamination detected in some products",
        "Genetic polymorphisms identified as a risk factor"
      ]
    }
  },
  "rehabilitation": {
    "title": "Rehabilitation by the Courts",
    "intro": "After years of legal disputes, German courts reached a clear conclusion. The Administrative Court of Cologne and later the Higher Administrative Court of Münster found that the ban was <strong>disproportionate</strong> and that the authorities had not correctly assessed the scientific evidence.",
    "quote": "\"The causality assumed by BfArM between the intake of Kava-containing medicines and the occurred liver damage is not sufficiently substantiated. The risk-benefit assessment was conducted incorrectly.\"",
    "quoteSource": "— OVG Münster, 2015"
  },
  "wissenschaft": {
    "title": "The Scientific Evidence",
    "intro": "After the ban, several comprehensive scientific evaluations were conducted, painting a more nuanced picture of Kava safety."
  },
  "whoBewertung": {
    "title": "WHO Assessment 2007",
    "intro": "The World Health Organization (WHO) conducted a comprehensive analysis of all available case reports in 2007. The results were revealing:",
    "analysisTitle": "WHO Analysis of 93 Case Reports",
    "cases": [
      {
        "count": "8",
        "label": "Cases \"probably\" causal",
        "color": "primary"
      },
      {
        "count": "53",
        "label": "Cases \"possible\" causal",
        "color": "amber"
      },
      {
        "count": "32",
        "label": "Cases not assessable",
        "color": "muted"
      }
    ],
    "note": "The WHO found that acetonic and ethanolic extracts posed a higher risk than synthetic Kavalactones, indicating non-Kavalactone components as a possible cause."
  },
  "emaBewertung": {
    "title": "EMA Assessment 2017",
    "intro": "The European Medicines Agency (EMA) published a 103-page assessment report in 2017 summarizing all available data:",
    "findings": [
      {
        "label": "Clinical Studies",
        "text": "No significant hepatotoxicity in controlled studies"
      },
      {
        "label": "Side Effects",
        "text": "Only mild, reversible transaminase elevations in a few subjects"
      },
      {
        "label": "Risk Factors",
        "text": "Organic extracts, alcohol, pre-existing liver disease, genetic polymorphisms"
      }
    ]
  },
  "klinischeStudien": {
    "title": "Evidence from Clinical Studies",
    "intro": "A particularly important point: In controlled clinical studies with standardized Kava preparations, <strong>no severe liver damage</strong> was observed. A systematic review by Smith & Leiras (2018) analyzed 11 randomized studies and found no evidence of hepatotoxicity.",
    "tableTitle": "Summary of Study Findings",
    "headers": [
      "Study",
      "Participants",
      "Duration",
      "Liver Damage"
    ],
    "studies": [
      {
        "study": "Sarris et al. (2013)",
        "participants": "75",
        "duration": "6 weeks",
        "result": "None"
      },
      {
        "study": "Boerner et al. (2003)",
        "participants": "129",
        "duration": "8 weeks",
        "result": "None*"
      },
      {
        "study": "Lehrl (2004)",
        "participants": "40",
        "duration": "4 weeks",
        "result": "None"
      },
      {
        "study": "Cochrane Review (2003)",
        "participants": "645 (7 studies)",
        "duration": "1-24 weeks",
        "result": "None"
      }
    ],
    "footnote": "*Mild transaminase elevations in 2 subjects, one had already elevated baseline values"
  },
  "risikofaktoren": {
    "title": "Identified Risk Factors",
    "intro": "Scientific research has identified several factors that may increase the risk of hepatic side effects. Understanding these factors allows for safe use."
  },
  "extrakte": {
    "title": "Extract Types: Aqueous vs. Organic",
    "intro": "A central finding of the WHO analysis was the difference between various extraction methods:",
    "waessrig": {
      "title": "Aqueous Extracts (traditional)",
      "items": [
        "Traditional preparation method",
        "Primarily extracts Kavalactones",
        "Contains protective glutathione",
        "No documented hepatotoxicity in Pacific populations",
        "Classified as safe by FAO/WHO"
      ]
    },
    "organisch": {
      "title": "Organic Extracts (acetonic/ethanolic)",
      "items": [
        "Industrial extraction method",
        "Higher Kavalactone concentration",
        "Also extracts flavokavins",
        "Glutathione is not extracted",
        "Higher risk in WHO analysis"
      ]
    }
  },
  "pflanzenteile": {
    "title": "Plant Parts: Root vs. Above-Ground Parts",
    "intro": "The use of different plant parts has significant implications for safety:",
    "tableTitle": "Pipermethystin Content by Plant Part",
    "headers": [
      "Plant Part",
      "Pipermethystin",
      "Safety"
    ],
    "rows": [
      {
        "part": "Root/Rhizome",
        "content": "Not detectable",
        "safety": "Safe",
        "color": "primary"
      },
      {
        "part": "Stem Sheaths",
        "content": "Up to 0.85%",
        "safety": "Problematic",
        "color": "amber"
      },
      {
        "part": "Leaves",
        "content": "Approx. 0.2%",
        "safety": "Toxic",
        "color": "destructive"
      }
    ],
    "note": "Pipermethystin is an alkaloid that is highly cytotoxic in vitro and disrupts mitochondrial function (Nerurkar et al., 2004). It is found exclusively in above-ground plant parts."
  },
  "genetik": {
    "title": "Genetic Factors: CYP2D6 Polymorphisms",
    "intro": "Kavalactones are primarily metabolized through the cytochrome P450 enzyme system, particularly via CYP2D6. Genetic variants of this enzyme can significantly affect the metabolism rate:",
    "factors": [
      {
        "label": "Poor Metabolizers (PM)",
        "text": "About 5-10% of Europeans have reduced CYP2D6 activity, which can lead to higher Kavalactone levels"
      },
      {
        "label": "Idiosyncratic Reactions",
        "text": "Some cases may be due to immune-mediated mechanisms"
      }
    ]
  },
  "komedikation": {
    "title": "Comedication & Alcohol",
    "warning": {
      "title": "Critical Risk Factor",
      "text": "Combining Kava with alcohol or hepatotoxic medications significantly increases the risk of liver damage. In many of the original case reports, alcohol consumption was documented or not excluded."
    },
    "intro": "The WHO identified the following comedications as particularly problematic:",
    "items": [
      "Alcohol (synergistic hepatotoxicity)",
      "Paracetamol/Acetaminophen (hepatotoxic)",
      "Benzodiazepines (CYP interaction)",
      "Antipsychotics (CYP interaction)",
      "Statins (hepatotoxic potential)"
    ]
  },
  "mechanismen": {
    "title": "Possible Mechanisms of Hepatotoxicity",
    "intro": "The exact mechanisms by which Kava can cause liver damage in rare cases are not yet fully understood. Several hypotheses are being discussed:",
    "hypotheses": [
      {
        "title": "1. Quinone Metabolites",
        "text": "Kavain and Dihydrokavain can be oxidized to reactive quinone metabolites that can react with cellular proteins and cause oxidative stress (Johnson et al., 2003). Glutathione can neutralize these metabolites – a possible reason why aqueous extracts (which contain glutathione) are safer."
      },
      {
        "title": "2. Flavokavins",
        "text": "Flavokavin B shows in vitro cytotoxicity and can induce apoptosis in hepatocytes. Organic extracts contain higher concentrations of flavokavins than aqueous preparations."
      },
      {
        "title": "3. Pipermethystin",
        "text": "This alkaloid from above-ground plant parts is highly hepatotoxic and disrupts mitochondrial function. It is not present in the root but can enter products through contamination."
      },
      {
        "title": "4. Idiosyncratic Reactions",
        "text": "Some cases may be due to immune-mediated, idiosyncratic reactions that occur independently of dose and are genetically determined."
      }
    ]
  },
  "empfehlungen": {
    "title": "Practical Recommendations for Safe Consumption",
    "intro": "Based on the scientific evidence, clear recommendations for safe Kava consumption can be derived:",
    "checklistTitle": "Checklist for Safe Kava Consumption",
    "items": [
      {
        "label": "Use only Noble Kava",
        "text": "Pay attention to the variety designation and buy from trusted sources"
      },
      {
        "label": "Use only root/rhizome",
        "text": "No products with leaves or stem sheaths"
      },
      {
        "label": "Prefer traditional aqueous preparation",
        "text": "Kneading or blender method with water"
      },
      {
        "label": "Do not consume alcohol",
        "text": "At least 24 hours before and after Kava consumption"
      },
      {
        "label": "Be aware of medication interactions",
        "text": "See Interactions"
      },
      {
        "label": "Avoid in liver diseases",
        "text": "See Contraindications"
      },
      {
        "label": "Maintain moderate dosing",
        "text": "No more than 250mg Kavalactones per day with regular consumption"
      }
    ],
    "selfObservation": {
      "title": "Note on Self-Observation",
      "text": "In case of unusual fatigue, yellowing of the skin or eyes, dark urine, or light-colored stool, Kava consumption should be stopped immediately and a doctor consulted. These symptoms may indicate liver problems."
    }
  },
  "quellen": {
    "title": "Sources & Further Reading",
    "officialReports": {
      "title": "Official Reports",
      "items": [
        {
          "author": "WHO (2007):",
          "title": "Assessment of the Risk of Hepatotoxicity with Kava Products.",
          "source": "World Health Organization Technical Report."
        },
        {
          "author": "FAO/WHO (2016):",
          "title": "Kava: A Review of the Safety of Traditional and Recreational Beverage Consumption.",
          "source": "FAO/WHO Technical Report."
        },
        {
          "author": "EMA (2017):",
          "title": "Assessment Report on Piper methysticum G. Forst., rhizoma.",
          "source": "EMA/HMPC/450589/2016."
        }
      ]
    },
    "reviews": {
      "title": "Scientific Reviews",
      "items": [
        {
          "author": "Teschke R. (2010):",
          "title": "Kava hepatotoxicity - a clinical review.",
          "source": "Annals of Hepatology."
        },
        {
          "author": "Teschke R., Lebot V. (2011):",
          "title": "Kava hepatotoxicity in traditional and modern use.",
          "source": "British Journal of Clinical Pharmacology."
        },
        {
          "author": "Sarris J. et al. (2011):",
          "title": "Kava: a comprehensive review of efficacy, safety, and psychopharmacology.",
          "source": "Australian & New Zealand Journal of Psychiatry."
        }
      ]
    },
    "moreStudies": "A complete list of all cited studies can be found on our",
    "studiesLink": "Studies page"
  }
}
